ImmuCell (ICCC) Stock Price, News & Analysis

Company Overview

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases. Through proprietary manufacturing processes, ImmuCell delivers bioactive immunoglobulins and immune-supporting factors to strengthen the health and survivability of young ruminants.

In addition to its passive immunology franchise, ImmuCell provides veterinary diagnostic assays and treatment products targeting common cattle diseases. Its in-house laboratory services encompass immunodiagnostic tests and therapeutic interventions aimed at improving udder health and controlling infectious conditions within herds across North America.

Since its founding, ImmuCell has cultivated partnerships with animal health professionals, distributors, and research organizations to expand its reach throughout the United States and into select international markets. The company is led by a management team with expertise in veterinary science, agriculture, and commercial operations, positioning it to advance innovative solutions for livestock producers worldwide.

Key Stats

• Today's Range: $6.06 to $6.35
• 50-Day Range: $5.65 to $6.80
• 52-Week Range: $3.38 to $7.60
• Volume: 8,929 shs
• Average Volume: 22,608 shs
• Market Capitalization: $54.75 million
• P/E Ratio: 31.84
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

ICCC Stock Analysis - Frequently Asked Questions

How have ICCC shares performed this year?

ImmuCell's stock was trading at $5.15 at the beginning of the year. Since then, ICCC stock has increased by 17.5% and is now trading at $6.05.

How were ImmuCell's earnings last quarter?

ImmuCell Corporation (NASDAQ:ICCC) announced its quarterly earnings results on Thursday, August, 14th. The biotechnology company reported $0.06 EPS for the quarter. The biotechnology company had revenue of $6.45 million for the quarter. ImmuCell had a trailing twelve-month return on equity of 6.25% and a net margin of 6.23%.
Read the conference call transcript.

How do I buy shares of ImmuCell?

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/19/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ICCC
• CIK: 811641
• Web: www.immucell.com
• Phone: (207) 878-2770
• Fax: 207-878-2117
• Employees: 70
• Year Founded: 1982

Profitability

• EPS (Trailing Twelve Months): $0.19
• Trailing P/E Ratio: 31.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.16 million
• Net Margins: 6.23%
• Pretax Margin: 6.27%
• Return on Equity: 6.25%
• Return on Assets: 3.87%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 3.85
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: $26.49 million
• Price / Sales: 2.07
• Cash Flow: $0.06 per share
• Price / Cash Flow: 94.25
• Book Value: $3.09 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 9,050,000
• Free Float: 8,539,000
• Market Cap: $54.75 million
• Optionable: Not Optionable
• Beta: 0.30